Pajjiż: Ingilterra
Lingwa: Ingliż
Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)
Lisinopril
Zentiva Pharma UK Ltd
C09AA03
Lisinopril
5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050501; GTIN: 5000283630654
Package Leaflet: Information for the User ZESTRIL ® 5MG TABLETS (LISINOPRIL) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The name of this medicine is Zestril ® 5mg Tablets but will be referred to as Zestril throughout the remainder of this leaflet. Zestril is also available in other strengths. WHAT IS IN THIS LEAFLET: 1. What Zestril is and what it is used for 2. What you need to know before you take Zestril 3. How to take Zestril 4. Possible side effects 5. How to store Zestril 6. Contents of the pack and other information 1. WHAT ZESTRIL IS AND WHAT IT IS USED FOR Zestril contains a medicine called lisinopril. This belongs to a group of medicines called ACE inhibitors. Zestril can be used for the following conditions: To treat high blood pressure (hypertension). To treat heart failure. If you have recently had a heart attack (myocardial infarction). To treat kidney problems caused by Type II diabetes in people with high blood pressure. Zestril works by making your blood vessels widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZESTRIL DO NOT TAKE ZESTRIL: if you are allergic to lisinopril or any of the other ingredients of this medicine (listed in section 6). if you have ever had an allergic reaction to another ACE inhibitor medicine. The allergic reaction may have caused swelling of the hands, feet, ankles, face, lips, tongue or throat. It may also have made it Aqra d-dokument sħiħ
1 NAME OF THE MEDICINAL PRODUCT LISINOPRIL 5mg TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5mg of Lisinopril as Lisinopril dihydrate. For the full list excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet White, round, flat 8 mm tablets, scored on both sides. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Hypertension: Treatment of hypertension. • Heart failure: Treatment of symptomatic heart failure. • Acute myocardial infarction: Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction. • Renal complications of diabetes mellitus: Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Lisinopril should be administered orally in a single daily dose. As with all other medication taken once daily, lisinopril should be taken at approximately the same time each day. The absorption of lisinopril tablets is not affected by food. The dose should be individualised according to patient profile and blood pressure response (see section 4.4). HYPERTENSION Lisinopril may be used as monotherapy or in combination with other classes of antihypertensive medicinal products (see sections 4.3, 4.4, 4.5 and 5.1). • Starting dose In patients with hypertension the usual recommended starting dose is 10mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5-5mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (see Table 1 below). • Maintenance dose The usual effective maintenance dosage is 20mg admin Aqra d-dokument sħiħ